New updates have been reported about Antheia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antheia has appointed Dr. Chris Savile as Vice President of Business Development and Partnerships, signaling a more aggressive commercial phase for its advanced biosynthesis platform and expanding portfolio of critical pharmaceutical ingredients. Savile will lead the sourcing and structuring of strategic alliances to broaden Antheia’s ingredient pipeline and deepen adoption of its platform among global pharmaceutical manufacturers.
CEO and co-founder Dr. Christina Smolke said industry collaboration is now central to Antheia’s growth strategy as it scales a diversified portfolio of essential drug ingredients and converts its technical edge into broader market penetration. Savile, formerly CEO of Willow Biosciences and a senior executive at Intrexon and Codexis, brings two decades of experience in translating complex biotechnologies into commercial partnerships, a capability that will be key as Antheia builds on its recent Series C extension and an expanded U.S. government agreement to onshore pharmaceutical supply chains.